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Chemokines  are  chemoattractant  cytokines  that  mediate  the  migration  of  immune  cells  to  sites  of infec-
tion which  play  an  important  role in  innate  and  adaptive  immunity.  As  an  immune  evasion  strategy,
large  DNA  viruses  (herpesviruses  and  poxviruses)  encode  soluble  chemokine  binding  proteins  that  bind
chemokines  with  high  afﬁnity,  even  though  they  do not  show  sequence  similarity  to cellular  chemokine
receptors.  This  review  summarizes  the  different  secreted  viral  chemokine  binding  proteins  described  to
date, with  special  emphasis  on  the  diverse  mechanisms  of action  they  exhibit  to  interfere  with  chemokine
function  and  their  speciﬁc  contribution  to  virus  pathogenesis.
© 2015  Elsevier  B.V.  All  rights  reserved.
1. Introduction
Viral infection stimulates the production of cytokines and
chemokines that trigger an immune response that can eliminate
the invading virus. Interferons (IFNs) and tumor necrosis factor
(TNF) are cytokines that induce anti-viral states or apoptosis within
the innate immune response (Biron, 2001; Guidotti and Chisari,
2000). Chemokines are chemotactic cytokines that play a crucial
role in inducing the migration of immune cells to areas of infection
(Baggiolini, 1998). They are classiﬁed into four classes: C, CC, CXC
and CX3C chemokines according to the position of the N-terminal
cysteine residue(s) (Zlotnik and Yoshie, 2000). Chemokines are
secreted from the cell and immobilized on the cell surface through
their interaction with glycosaminoglycans (GAGs) and establish
a concentration gradient that is important to direct leukocytes
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to sites of infection (Handel et al., 2005; Johnson et al., 2005).
Immune cells are activated through speciﬁc high afﬁnity interac-
tions between chemokines and the G-protein coupled receptors
(GPCRs) (Blanpain et al., 2003; Proudfoot, 2002; Zlotnik et al., 2006)
(Fig. 1A). The three-dimensional fold of all monomeric chemokines
is conserved. The N-loop is followed by a 310 helix, the three -
strands form a -pleated sheet and these are connected by the 30’s
and 40’s loops. The 50’s loop connects the last secondary struc-
tural, a C-terminal -helix (Fernandez and Lolis, 2002) (Fig. 2A).
Chemokines interact with GPCRs and GAGs through distinct bind-
ing sites that may  overlap.
Poxviruses and herpesviruses are large DNA viruses that ded-
icate a great part of their genetic information to escape and
modulate the host immune response (Finlay and McFadden, 2006;
Seet et al., 2003a). Variola virus (VARV), a member of the poxvirus
family, was the causative agent of smallpox, one of the most
virulent human diseases (Smith and McFadden, 2002), and vac-
cinia virus (VACV) is the vaccine used to eradicate smallpox by
1980. Ectromelia virus (ECTV) causes a smallpox-like disease in
mice, cowpox virus (CPXV) is a rodent virus of broad host range
that causes sporadic infections in other mammals, and myxoma
virus (MYXV) causes myxomatosis in rabbits. Animal infections
with VACV, ECTV, CPXV and MYXV are used as models to study
poxvirus pathogenesis and their interaction with the immune sys-
tem. The herpesvirus family includes important human pathogens
such as herpes simplex virus (HSV), varicella zoster virus or
cytomegalovirus.
Poxviruses and herpesviruses have evolved a variety of mecha-
nisms to evade their destruction by the host immune system. One
http://dx.doi.org/10.1016/j.virusres.2015.02.028
0168-1702/© 2015 Elsevier B.V. All rights reserved.
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Fig. 1. Different mechanisms of interaction between viral CKBPs and chemokines. (A) Leukocytes are recruited into the inﬂamed tissue through the interaction of chemokines
presented on the surface of GAGs. First, leukocytes roll on the endothelial surface through low afﬁnity interactions. The high afﬁnity interaction between chemokines and
GPCRs  on leukocyte triggers the extravasation of the cell to sites of infection. (B) Virus-encoded CKBPs may  bind the chemokines through their GAG  binding domain (GAG
BD)  or their GPCR binding domain (GPCR BD), (C) Viral CKBPs may simultaneously interact with GAGs to anchor the CKBP to the cell surface.
of these strategies is the expression of proteins that interfere and
modulate the chemokine system, including viral chemokine homo-
logues, viral chemokine receptor homologues and viral chemokine
binding proteins (CKBPs) (Alcami, 2003; Alcami and Koszinowski,
2000). CKBPs are secreted proteins with no sequence similarity to
their cellular counterparts and can interrupt the chemokine func-
tion via distinct mechanism of action, abrogating the formation of
the chemokine gradient or the interaction between chemokines
and their speciﬁc cellular receptor (Fig. 1B and C). CKBPs
have been found in non-viral pathogens such as the trematode
Fig. 2. Structure of CKBPs. (A) Structure of the CXCL12 chemokine (PDB: 1A15) (Dealwis et al., 1998). The three antiparallel -strands are shown in yellow, the single turn of
a  310 helix is represented in blue and the C-terminal -helix is represented in magenta. (B) Structure of the M3  protein (PDB: 1MKF). The C-terminal domain is represented
in  magenta and the N-terminal domain (NTD) is represented in green. (C) Structure of the SECRET domain of CrmD (PDB: 3ON9), the 35-kDa (PDB: 1CQ3) and A41 (PDB:
2VGA) CKBPs. The three proteins share the same -sandwich structure topology but have different connecting loops that are represented in magenta. The -sheet II and the
-sheet  I are represented in red and in blue, respectively, in the A41 protein. All the structures were created using Open-Source PyMOL (http://pymol.org/).
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Schistosoma mansoni (Smith et al., 2005) and ticks (Deruaz et al.,
2008; Frauenschuh et al., 2007). More recently, a human soluble
CKBP has been described (Dyer et al., 2014).
We  focus this review on the mechanism of action of the virus-
encoded CKBPs and their role in immune evasion and pathogenesis.
2. Poxvirus
2.1. The poxvirus 35-kDa protein
The major secreted protein of 35 kDa encoded by VACV strains
Lister and rabbitpox was identiﬁed as a CKBP that inhibits CC
chemokine activity (Alcami et al., 1998; Graham et al., 1997; Smith
et al., 1997) (Table 1). This protein is expressed by many poxviruses,
including VARV, CPXV, ECTV and MYXV. The 35-kDa protein has
been shown to bind with high afﬁnity (in the low nanomolar range)
to nearly all human and mouse CC chemokines (Burns et al., 2002).
Low afﬁnity binding to CXCL1 and CXCL8 has been detected, but it
has not been possible to demonstrate binding to a range of other
CXC, C or CX3C chemokines (Alcami et al., 1998; Burns et al., 2002;
Lalani et al., 1998; Smith et al., 1997). The mechanism of action of
the 35-kDa CKBP is competitive inhibition of CC-chemokine bind-
ing to cellular receptors (Fig. 1B), inhibiting their ability to induce
signal transduction and cell migration in vitro assays (Alcami et al.,
1998; Lalani et al., 1998; Smith et al., 1997). The 35-kDa protein of
MYXV also called M-T1, has the unique ability to interact with GAGs
and with chemokines simultaneously (Seet et al., 2001), allowing
the retention of the protein in the vicinity of infected cells and may
enhance its ability to protect the sites of infection from chemokine-
mediated anti-viral responses (Fig. 1C).
The three dimensional structure of several 35-kDa CKBPs have
been described to date. The structure of the CPXV 35-kDa CKBP was
determined by X-ray crystallography, and it was shown to be a com-
pact globular protein with a unique sandwich topology (Fig. 2C).
The -sandwich domain is composed of two -sheets, parallel to
each other, two short -helices, and a few large loops connecting
these secondary elements (Carﬁ et al., 1999). A patch of conserved
negatively charged residues on the exposed face of -sheet II were
suggested as a chemokine-binding site. The structure of 35-kDa
of ECTV was reported later and conﬁrmed the general sandwich
folding of this family of CKBPs (Arnold and Fremont, 2006). The
residues in the CKBP that are essential in the interaction with the
CCL2 and CCL3 chemokines was determined by mutagenesis and
showed that are localized at the -sheet II and in the 2–4 loop.
Further structural studies in solution by nuclear magnetic reso-
nance determined the structure of 35-kDa VACV strain rabbitpox
and human CCL4 complex. This study conﬁrmed that the 35-kDa
CKBP uses residues from the -sheet II to interact with surface of
the chemokine that includes residues adjacent to its N-terminal
region, as well as residues in the 20’s region and the 40’s loop
(Zhang et al., 2006) and established the structural basis for the abil-
ity of this CKBP to promiscuously recognize CC chemokines. These
results conﬁrmed the previous binding studies with CCL2 mutants
that identiﬁed the amino acid residues required for high afﬁnity
interaction with the VACV 35-kDa CKBP which were similar to those
involved in CCL2-CCR2b chemokine receptor binding (Beck et al.,
2001; Seet et al., 2001). The structural insights into the interaction
between 35-kDa and CCL11 complex studied by nuclear magnetic
resonance and ﬂuorescence anisotropy are similar to those of the
35-kDa and CCL4 complex. The -sheet II and the highly positive
and quite ﬂexible loop between the -2 and -3 strands exhibit
interactions with the N-loop, 20’s region, 40’s loop and the third -
strand of CCL11. The 35-kDa protein recognizes epitopes that are
relatively rigid and conserved among CC chemokines (Kuo et al.,
2014).
In order to know the role of this CKBP in viral pathogenesis vari-
ous laboratories constructed recombinant viruses to inactivate the
35-kDa gene. Insertional mutation of the M-T1 gene in MYXV had no
signiﬁcant effects on disease progression or in the overall mortality
rate of infected rabbits but increased the inﬁltration of leukocytes
in primary infection sites during the initial 2–3 days of infection
(Lalani et al., 1999). Similar conclusions have been shown in mice
infected with a mutant rabbitpox virus, a VACV strain, in which the
35 kDa gene was inactivated (Graham et al., 1997). The same rabbit-
pox virus mutant appeared to induce an earlier onset of symptoms
and more severe illness at sub-lethal doses than wild type virus
(Martinez-Pomares et al., 1995). The expression of the 35-kDa pro-
tein from VACV strain Western Reserve (WR), a strain that does not
encode the CKBP, caused a slight attenuation of the virus associated
with reduced inﬂammatory pathology in the lungs, suggesting that
this CKBP may  attenuate the immune-mediated pathology caused
by VACV infection (Reading et al., 2003).
Some reports have demonstrated the potential therapeutics
effects of the 35-kDa protein in inﬂammatory diseases such as
atherosclerosis (Bursill et al., 2009) or arthritis (Buatois et al.,
2010). In another study, a series of novel 35-kDa-Fc fusion pro-
teins were constructed, and one of these mutant proteins shows
increased potency of CC chemokine blockade and enhanced anti-
inﬂammatory activity (White et al., 2011).
2.2. The A41 family of poxvirus CKBPs
VACV A41 is an immunomodulatory protein that is expressed
early and late during infection and is highly conserved among
poxviruses. The A41 glycoprotein shares sequence similarity to the
35-kDa CKBP from VACV and other poxviruses (Ng et al., 2001). Two
different groups carried out an extensive screening of chemokines
by surface plasmon resonance for their potential binding to recom-
binant A41 from ECTV (E163) and VACV, and they reported the
identiﬁcation of a reduced set of CC and CXC chemokines that inter-
acts with the A41 protein with high afﬁnity (Bahar et al., 2008;
Ruiz-Arguello et al., 2008) (Table 1). In contrast to the poxvirus
35-kDa CKBP, the interaction of A41 with chemokines is inhibited
in the presence of GAGs and the A41 protein does not block cel-
lular migration induced by chemokines in vitro. By using mutant
forms of CXCL10 and CXCL12 chemokines with reduced ability
to interact with chemokine receptors or GAGs, it was shown that
the ECTV E163 protein interacts with the GAG-binding domain of
chemokines (Ruiz-Arguello et al., 2008). It was suggested that the
inhibition of leukocyte migration in vivo may  be related to the
ability of A41 to block the correct interaction of chemokines with
GAGs, which is required for appropriate chemokine function in vivo
(Handel et al., 2005; Johnson et al., 2005). In addition to its interac-
tion with chemokines, the ECTV E163 CKBP can also interact with
high afﬁnity with GAGs, enabling E163 to attach to cell surfaces and
to remain in the vicinity of the sites of viral infection (Fig. 1C).
Despite sharing only approximately 20% sequence identity with
the 35-kDa CKBP, the crystal structure of the A41 protein revealed
a globular -sandwich domain similar to that of the 35-kDa CKBP
family (Bahar et al., 2008) (Fig. 2C), but it has notable structural
differences particularly in surface loops and electrostatic charge
distribution. The highly acidic loop between strands 2 and 4 present
in the 35-kDa CKBP is absent in the A41 protein and may  restrict the
selectively of the A41 protein to only a few chemokines. Although
the A41-chemokine complex has not been crystallized, structural
modeling suggested that the interaction of A41 and 35-kDa proteins
with chemokines involves the same domains (Bahar et al., 2008).
The A41 and 35-kDa CKBPs from poxviruses are structurally related
but block the chemokine system in different but complementary
ways (Fig. 1B and C), which is advantageous for the virus to control
the host anti-viral responses.
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Table  1
CKBPs encoded by viruses: structure, binding properties and contribution to virulence.
CKBP Species CKs and mechanism of
action
Deletion mutant phenotype Structure/PBD References
Poxvirus
35-kDa ECTV, CPXV,
VACV, MYXV
Binds CC chemokines,
preventing interaction
with speciﬁc receptors.
Inhibits cell migration.
MYXV MT1 also interacts
with GAGs of cellular
surface.
35 kDa-RPXV: ID infection of
rabbits. Increased leukocyte
inﬁltration during the early
phases of infection.
35kDa-RPXV: IN infection of
mice. An earlier onset and
more severe illness at
sub-lethal doses.
ID infection of rabbits, no
differences.
MT1-MYXV: ID infection of
rabbits, increase in inﬁltrating
leukocytes at the primary site
of  virus inoculation.
35-kDa CPXV: 1CQ3
35-kDa ECTV: 2GRK
35-kDA VACV/CCL4 (complex): 2FFK
Alcami et al.
(1998), Arnold and
Fremont (2006),
Burns et al. (2002),
Carﬁ et al. (1999),
Graham et al.
(1997), Lalani et al.
(1998, 1999),
Martinez-Pomares
et al. (1995), Seet
et al. (2001), Smith
et al. (1997) and
Zhang et al. (2006)
CBP ORFV Binds CC and C chemokines
through their receptor
binding domain. Inhibits
chemokine signaling.
ND ND Seet et al. (2003a,b)
A41 VACV, ECTV Binds CC and CXC
chemokines through their
GAG binding domain.
Interacts with cell surface
GAGs.
Does not inhibit
chemotaxis in vitro.
A41L-VACV: ID infection of
mice. More severe lesions
than wild type virus.
A41L-VACV: IN infection of
mice. Mice lost more weight
than those infected with wild
type virus.
A41-VACV: 2VGA Bahar et al. (2008),
Clark et al. (2006),
Ng et al. (2001) and
Ruiz-Arguello et al.
(2008)
M-T7 MYXV Binds C, CC and CXC
chemokines through their
GAG binding domain.
MT7-MYXV: Attenuated in
rabbit infections.
ND Lalani et al. (1997)
and Mossman et al.
(1996)
SECRET domain VARV, ECTV,
CPXV, VACV
Interacts with limited
number of CC and CXC
chemokines through the
receptor binding domain.
Inhibits
chemokine-induced
migration.
SCP(B7)VACV-WR: IN
infection without phenotype
but in ID model was
attenuated (Balb/c mice).
CrmB-CPXV-BR: Attenuated.
IC  infection (Balb/c mice).
CrmD SECRET ECTV: 3ON9
CrmD SECRET ECTV/CXCL3 (complex):
3ONA
Alejo et al. (2006),
Palumbo et al.
(1994), Price et al.
(2000) and Xue
et al. (2011)
Herpesvirus
gG EHV-1, EHV-3,
BHV-1, BHV-5,
FeHV-1, RanHV
ILTV, PRV,
Bind CC and CXC
chemokines through
receptor binding domain.
EHV-1 gG also prevents
chemokine binding to
GAGs.
ILTV-1: Attenuated in natural
host.
EHV: Exacerbation of
respiratory disease in mice,
exclusively at low doses of
infection.
PRV: No phenotype (pigs).
ND Bryant et al. (2003),
Costes et al. (2005),
Van de Walle et al.
(2007),
Viejo-Borbolla et al.
(2010a,b) and von
Einem et al. (2007)
gG1, gG2 HSV-1
HSV-2
Bind CC and CXC
chemokines through the
GAG binding domain,
Enhance chemokine
activity.
HSV-1: Attenuated in ID
infection of mice.
HSV-2: ND
ND Balan et al. (1994),
Meignier et al.
(1988),
Viejo-Borbolla
et al. (2012) and
Weber et al. (1987)
M3  MHV-68 Binds CC, CXC, C and CX3C
chemokines. Blocks
through receptor binding
domain and also GAGs
binding domain.
IC injection of C57BL/6 and
CD-1 mice: Attenuated.
IN inoculation of C57BL/6
mice: No phenotype.
IN Infection of wood mice:
Reduced latency and
attenuated.
M3: 1MKF
M3/MCP-1 (complex): 1ML0
M3/CCL2: (complex): 2NZ1
M3/CXCL1: (complex): 2NYZ
Alexander et al.
(2002), Hughes
et al. (2011), Parry
et al. (2000) and
van Berkel et al.
(2002)
pUL21.5 HCMV Blocks CCL5 through the
receptor binding domain.
ND ND Wang et al. (2004)
R17 RHVP Binds C and CC chemokines
through the receptor
binding domain and
directly binds to cellular
GAGs.
ND ND Lubman et al.
(2014)
Routes of infection: IC, intracranial; ID, intradermal; IN, intranasal.
BHV, bovine herpesvirus; EHV, equine herpesvirus; FeHV, feline herpesvirus; ILTV, infectious laryngotracheitis virus; PRV, pseudorabies virus; RanHV, rangiferine herpesvirus;
RPXV,  rabbit poxvirus.
Deletion of the A41L gene from VACV strain WR  enhanced lesion
size and altered the inﬂammatory response to infection in a mouse
dermal model (Ng et al., 2001), and the deletion mutant was slightly
more virulent than the wild type virus after intranasal infection
with low virus doses (Clark et al., 2006). The deletion of the A41L
gene from VACV strain modiﬁed virus Ankara induces a better pro-
tection than wild type virus against a lethal infection with VACV
WR (Clark et al., 2006) and a VACV strain modiﬁed virus Ankara
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recombinant lacking the A41L gene together with the B16R gene,
encoding a secreted interleukin-1  receptor, induces better HIV-1
adaptive and memory responses (Garcia-Arriaza et al., 2010).
2.3. The M-T7 protein encoded by MYXV
Initial work identiﬁed the MYXV M-T7 gene encoding an abun-
dant 37-kDa glycoprotein that is secreted from infected cells (Upton
et al., 1992). This protein has signiﬁcant sequence similarity to the
human and mouse IFN receptors (IFN-Rs) and was shown to bind
to and inhibit the biological activity of rabbit IFN in a species-
speciﬁc manner (Mossman et al., 1995; Upton et al., 1992).
The M-T7 CKBP was also found to bind a broad range of C, CXC
and CC chemokines. A CXCL8 partial C-terminal truncated vari-
ant, which displays a markedly lower heparin afﬁnity than does
its full-length counterpart, was unable to bind M-T7 (Lalani et al.,
1997). Also, they observed that M-T7 is not able to bind to the
CXCL8 mutant, which lacks the C-terminal -helix and displays no
heparin binding. Heparin competition studies were performed, and
they showed that heparin acts as a speciﬁc competitor for displac-
ing the binding of chemokine to M-T7. The binding of M-T7 with
CXCL8 may  be analogous to the interaction between chemokine
and heparin (Lalani et al., 1997) (Fig. 1B and Table 1). This ﬁnding
was unexpected and is a unique property of the IFN-R encoded
by MYXV since the IFN-R orthologue encoded by VACV does not
bind chemokines (Alcami et al., 1998; Lalani et al., 1997; Ruiz-
Arguello et al., 2008). The interaction of the M-T7 protein with
the chemokine GAG binding domain led to the suggestion that M-
T7 might prevent the correct localization of chemokines and the
formation of a chemokine gradient, rather than the blockade of
chemokine binding to speciﬁc receptors (Lalani et al., 1997).
Infection of European rabbits with a MYXV mutant in which both
copies of the M-T7 gene were disrupted demonstrated that the M-
T7 protein plays a signiﬁcant role in MYXV pathogenesis (Mossman
et al., 1996). The recombinant virus was signiﬁcantly attenuated in
rabbits, and decreased viral dissemination and lower viral titers
were observed at secondary sites of infection. Also, marked differ-
ences were seen in the size and progression of skin lesions, and
the onset and severity of secondary bacterial infections. However,
these results are difﬁcult to interpret because M-T7 targets IFN-
and chemokines, and both have important roles in inﬂammatory
responses.
MT-7 prevents chronic rejection in rat renal allografts, reduces
aortic allograft vasculopathy, delays the inﬂux of macrophages and
modulates angiogenesis in the foreign body response (Bedard et al.,
2003; Boomker et al., 2005; Liu et al., 2004). Also, recent studies
suggest that the anti-inﬂammatory activity of this protein in rodent
models of angioplasty injury as well as aortic and renal transplant
is dependent of the ability of M-T7 to block chemokine-GAG inter-
actions (Bartee et al., 2013).
2.4. A family of poxvirus proteins containing the smallpox
virus-encoded chemokine receptor (SECRET) domain
The study of the VARV-encoded Cytokine response modiﬁer
B (CrmB) led us to the ﬁnding of the SECRET domain. CrmB is
one of the four tumor necrosis factor receptor (TNFR) homologues
encoded by poxviruses, named CrmB, CrmC, CrmD and CrmE. The
N-terminal portion of these TNFRs is composed of cysteine-rich
domains of the mammalian counterparts that interact with TNF
(Hu et al., 1994; Loparev et al., 1998; Saraiva and Alcami, 2001;
Smith et al., 1996). The only TNFRs encoded by VARV (CrmB) and
ECTV (CrmD), have an additional C-terminal extension for which
no sequence similarity to host proteins was found, and it was
named SECRET domain. An extensive screening by surface plas-
mon  resonance of all human and mouse chemokines showed that
CrmB interacted with high afﬁnity with a limited set of chemokines
(Alejo et al., 2006) (Table 1). The restricted chemokine binding
speciﬁcity of the SECRET domain differs from the broad bind-
ing speciﬁcity of the previously identiﬁed CKBPs. The analysis
of poxviral genomes has identiﬁed other gene products encod-
ing SECRET domain-containing proteins (SCPs). The secreted CPXV
strain Brighton Red protein V218 and the ECTV strain Naval pro-
teins E12 and E184 were shown to bind chemokines and named
SCP-1, 2 and 3, respectively (Alejo et al., 2006).
The ability of VARV CrmB, CPXV CrmB, ECTV CrmD and CPXV
SCP-1 to inhibit chemokine-induced migration in vitro has been
demonstrated, suggesting that they interrupt the receptor binding
site of the chemokine. The fact that all members of the SECRET fam-
ily bind the same set of chemokines, despite their low sequence
similarity, suggests that the SECRET domain has a speciﬁc fold-
ing to bind chemokines either independently or fused to TNFRs.
De novo modeling of VARV CrmB SECRET domain spatial structure
revealed structural homology with CPXV 35-kDa and VACV A41
proteins (Antonets et al., 2010). The three dimensional structure of
the SECRET domain alone or complexed with a low afﬁnity bind-
ing chemokine, CX3CL1, was  solved and conﬁrmed that it shares
the same -sandwich topology with the 35-kDa and A41 poxvirus
CKBPs (Xue et al., 2011) (Fig. 2C).
The identiﬁcation of the SECRET domain in ﬁve different
poxvirus proteins is intriguing. This distribution may  explain, in
part, the variety of genes encoding TNFR homologues in poxvirus
genomes, some of which (CrmB and CrmD) encode this additional
chemokine-inhibitory activity. The information on the role of the
SECRET domain in viral pathogenesis is limited. Deletion of the SCP
B7 gene encoded by VACV strain WR had no major effects on vir-
ulence but in a murine intradermal model induced smaller lesions
than the control viruses (Price et al., 2000). The CPXV CrmB pro-
tein, which blocks both TNF and chemokines in vitro (Alejo et al.,
2006), has anti-inﬂammatory potential in vivo with an approxi-
mately 50-fold increase in LD50 in infected mice (Palumbo et al.,
1994). The MYXV M-T2 protein, a secreted TNFR sharing the same
domain organization as CrmB and CrmD, acts as a virulence factor
in European rabbits causing a slight reduction of mortality (Upton
et al., 1991). However, none of these studies have deﬁned the con-
tribution of the anti-TNF versus anti-chemokine domains present
in CrmB and CrmD to immune regulation and virulence.
The use of the ECTV CrmD protein as a potential therapeutic
revealed that it inhibits the development of ileitis by locally affect-
ing both TNF and chemokine function in the ileum of transgenic
mice expressing CrmD in intestinal epithelial cells (Viejo-Borbolla
et al., 2010a).
2.5. The Orf virus (ORFV) CKBP
ORFV is a parapoxvirus that causes infections in sheep and cat-
tle, and sporadically in humans. ORFV is usually not fatal but can
be severe in young animals infected for the ﬁrst time (Haig and
Fleming, 1999). It was shown that ORFV encodes a secreted protein
that is most closely related to the ORFV granulocyte macrophage-
colony stimulating factor inhibitory protein and also to the 35-kDa
CKBP family with only 12–18% identity. As described for the 35-kDa
CKBP, this ORFV protein binds CC chemokines with high afﬁnity
but it also interacts with the C chemokine lymphotactin, showing a
broader chemokine binding speciﬁcity (Seet et al., 2003b) (Table 1).
The ORFV CKBP is able to inhibit cellular chemotaxis in vitro (Lateef
et al., 2009, 2010) and the interaction with the chemokines is medi-
ated by the GPCR binding domain (Seet et al., 2003b). Dynamic light
scattering analysis suggests that the ORFV CKBP is a dimer in solu-
tion but the three dimensional structure has not yet been solved
(Counago et al., 2010).
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It has been demonstrated that the ORFV CKBP is a potent
inhibitor of inﬂammatory monocyte recruitment in a mouse skin
model (Lateef et al., 2009), and inhibits the recruitment of dendritic
cells to sites of skin inﬂammation, their migration to peripheral
lymph nodes and the T responsiveness in the inguinal lymph nodes
(Lateef et al., 2010).
3. Herpesvirus
3.1. The M3  protein encoded by murine gammaherpesvirus 68
(MHV-68)
M3  was identiﬁed as a broad spectrum CKBP, which is abun-
dantly secreted during acute infection of MHV-68 (Parry et al.,
2000; van Berkel et al., 2000), a pathogen of wild rodents. M3  is
able to bind promiscuously, but with high afﬁnities, to human and
murine chemokines belonging to all chemokine classes (Table 1).
A dual anti-chemokine function for M3  has been proposed.
On the one hand, and similar to the poxvirus 35-kDa protein, it
is able to bind free chemokines with high afﬁnity and to block
chemokine–receptor interactions by competitive inhibition. On the
other hand, although M3  is unable to bind GAGs directly it inhibits
the interaction of chemokines with GAGs affecting the chemotactic
gradients necessary for directed cell migration (Webb et al., 2004).
Moreover, M3  has been shown to disrupt preformed chemokine-
GAGs in vitro.
Structural studies of M3-chemokine complexes have revealed
the structural basis for this dual anti-chemokine function
(Alexander et al., 2002; Alexander-Brett and Fremont, 2007; Webb
et al., 2003). Crystallographic structures of M3  complexed with
CCL2 or XCL1 have revealed that the M3  C-terminal domain
engages with those conserved residues from diverse chemokine
subclasses involved in receptor binding with the same overall bind-
ing geometry (Alexander et al., 2002; Webb et al., 2003). Indeed, the
promiscuous chemokine binding by M3  could be facilitated by the
ﬂexibility of contact loops and certain domains of the M3  dimer
that mimic  the CCL2-interacting structure of its receptor CCR2
(Alexander et al., 2002). However, the M3  ability of blocking the
chemokine–GAG interaction relies on its acidic N-terminal domain
which exhibits electrostatic complementarity allowing engage-
ment with chemokine basics clusters involved in GAG association.
Interestingly, the N-terminal domain of M3  has structural similari-
ties to the poxvirus SECRET domain and the 35-kDa and A41 CKBPs
(Fig. 2B and C).
After intranasal infection, MHV-68 replicates transiently in
respiratory epithelial cells and spreads to lymphoid tissue where
latency is established in B lymphocytes, macrophages and dendritic
cells. In vivo studies using M3  deletion mutants of MHV-68 have
provided contradictory results and highlighted the relevance of the
animal model used in these studies. An initial report showed that
targeted disruption of the M3  gene had surprisingly little effect on
lytic virus replication in the respiratory tract or the initial spread of
virus to lymphoid tissues after intranasal inoculation (Bridgeman
et al., 2001) in C57BL/6 mice. However, the mutant virus failed
to establish normal levels of latency in splenic B cells. Interest-
ingly, in vivo CD8+ T cell depletion largely reversed the phenotype,
suggesting that chemokine neutralization by M3  may  function to
block CD8+ T cell recruitment into lymphoid tissue and to enable
the establishment of MHV-68 latency. A second report assigned an
attenuated phenotype to the M3  deletion mutant in an intracra-
nial model of infection using CD-1 and C57BL/6 mice, but not in the
intranasal model (van Berkel et al., 2002). Recently, a study using
wood mice (the natural host of MHV-68) showed that the lack of
M3 signiﬁcantly reduced the ability of MHV-68 to establish latency
in lung and spleen (Hughes et al., 2011).
3.2. The glycoprotein G (gG) encoded by alphaherpesviruses
gG from alphaherpesviruses is a component of the viral parti-
cle which is expressed as a membrane-anchored glycoprotein at
the plasma membrane of infected cells. After proteolytic cleav-
age of this membrane form, an additional secreted version of
gG (SgG) is released into the medium of infected cells. To date,
chemokine binding activity has been identiﬁed in the supernatants
from diverse cells infected with animal alphaherpesvirus such as
equine herpesvirus 1 and 3, bovine herpesvirus 1 and 5, felid her-
pesvirus 1 or pseudorabies virus (Bryant et al., 2003; Costes et al.,
2005; Van de Walle et al., 2007; Viejo-Borbolla et al., 2010b). The
amino acid residues involved in gG interaction with chemokines
have been identiﬁed by mutagenesis of equine herpesvirus 1 gG
and expression of hybrid molecules with equine herpesvirus 4 gG,
an orthologue that does not bind chemokines (Van de Walle et al.,
2009) (Table 1).
Although initial studies did not ﬁnd chemokine binding
activity in supernatants from cells infected with human alphaher-
pesviruses, a recent report identiﬁed this activity in supernatants
from HSV-2-infected cultures (Viejo-Borbolla et al., 2012). However
chemokine-binding activity has not been detected in supernatants
from cells infected with HSV-1 or varicella zoster virus. With HSV-1
this is explained by gG not being secreted, and chemokine bind-
ing activity has been detected in the plasma membrane of cells
infected with wild type HSV-1 but not with a gG-deﬁcient HSV-1
mutant indicating that the membrane-anchored form also retains
chemokine binding activity (Viejo-Borbolla et al., 2012). In the case
of varicella zoster virus, the gene encoding gG is not present in the
viral genome (Gomi et al., 2002).
The interaction of recombinant SgGs from HSV-1 and HSV-2
with a variety of CC and CXC chemokines occurs with high afﬁnity
through the GAG-binding domain in the chemokine (Viejo-Borbolla
et al., 2012). The mechanism of action of SgGs from HSV is unique
among vCKBPs. Like almost all CKBPs, gG homologues encoded
by other animal alphaherpesviruses, bind a variety of chemokines
to interfere with chemokine interaction with cellular receptors or
impairing chemokine presentation to GAGs, resulting in the inhibi-
tion of cellular chemotaxis (Costes et al., 2005; Van de Walle et al.,
2007; Viejo-Borbolla et al., 2010b). On the contrary, the interaction
of SgGs from HSV-1 and HSV-2 with chemokines has the opposite
effect, the enhancement of chemokine function. Thus, the addition
of SgG has been recently shown to increase the in vitro CXCL12
induced cell migration and more importantly SgG from HSV-2 has
been shown in vivo to increase the CCL28-mediated chemotaxis of
leukocytes in a mouse air pouch model (Viejo-Borbolla et al., 2012).
Interestingly, felid herpesvirus 1 gG present at the surface of the
virion has also been demonstrated to bind chemokines (Costes et al.,
2005, 2006) raising the possibility that the incoming virion could
interfere with chemokine function. In the case of HSV, it should be
interesting to know whether gG incorporated into the virion enve-
lope enhances chemokine function as reported for recombinant
SgG.
Recombinant HSV-1 viruses lacking gG expression have been
tested in vivo in three different studies (Balan et al., 1994; Meignier
et al., 1988; Weber et al., 1987). In all cases, different degrees
of attenuation were observed, suggesting the contribution of
gG to HSV-1 pathogenesis. This attenuated phenotype might be
explained by the enhancement of chemokine function recently
reported for HSV-1 gG. The role of HSV-2 gG on pathogenesis
remains unclear since no gG deletion mutants have been reported
to date. Deletion of the gG gene from pseudorabies virus did not
affect virulence or immunogenicity in pigs (Kimman et al., 1992;
Thomsen et al., 1987). In the case of infectious laryngotracheitis
virus, an alphaherpesvirus that causes acute respiratory disease in
poultry, gG was  shown to bind with high afﬁnity murine CC and
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CXC chemokines and to inhibit leukocyte chemotaxis (Devlin et al.,
2010). The corresponding gG-deletion mutant exhibits an atten-
uated phenotype in its natural host compared to wild-type virus,
and it is an effective attenuated vaccine since it induces protec-
tion against disease following challenge with virulent virus (Devlin
et al., 2007).
Equine herpesvirus 1 gG has been shown to bind a broad range of
chemokines and to inhibit equine CXCL8 induced migration of neu-
trophils. As described for the MHV-68 M3  protein, it also prevents
the interaction of chemokines with GAGs (Bryant et al., 2003; Van
de Walle et al., 2007). The effect of equine hespervirus 1 gG deletion
on virus pathogenesis has been tested in mouse models of respira-
tory infection. However, depending on the mouse strain and dose
of virus used, the results obtained were different and a clear phe-
notype could not be assigned to this mutant (Van de Walle et al.,
2007; von Einem et al., 2007).
3.3. The human cytomegalovirus pUL21.5 protein
Human cytomegalovirus encodes a small secreted glycoprotein
which has been demonstrated to bind CCL5 with high afﬁnity and
to block the interaction of human CCL5 with speciﬁc cellular recep-
tors (Wang et al., 2004) (Table 1). In contrast to other virus-encoded
CKBPs, pUL21.5 appears to have an exquisite speciﬁcity for the
CCL5, but due to the limited number of cytokines tested in this study
the possibility that pUL21.5 could bind additional chemokines can-
not be ruled out. Although the exact role of this protein during
infection is not known, the mRNA encoding pUL21.5 is incorporated
into virions, suggesting that this CKBP could be expressed to mod-
ulate the host response even before the transcriptional activation
of the infecting viral genome (Wang et al., 2004).
3.4. R17, a potential CKBP from the recently characterized rodent
herpesvirus Peru
Rodent herpesvirus Peru is a recently characterized rhadi-
novirus related to MHV-68 and Kaposi’s sarcoma-associated
herpesvirus that establishes acute and latent infection in the lab-
oratory (Loh et al., 2011). Recently, R17 was identiﬁed, among the
secreted proteins encoded uniquely by rodent herpesvirus Peru, as
a CKBP. R17 binds members of 2 of 4 chemokine families (CC and
C) with high afﬁnities blocking their ability to trigger cell signaling
through chemokine receptors (Lubman et al., 2014). In addition to
chemokine binding, and unlike M3 from MHV-68, R17 can directly
bind to cell surface GAGs through two BBXB motifs that are com-
monly found in GAG binding proteins (Table 1). Therefore, R17
binding to chemokines and GAGs can occur simultaneously in two
different sites and could enhance the association of chemokines
with cell surfaces (Lubman et al., 2014).
4. The immune modulatory functions of virus-encoded
secreted CKBPs
The production of secreted versions of cytokine receptors that
bind cytokines with high afﬁnity and block their activity is a
strategy employed by the immune system of humans and mam-
mals to control the immune response and prevent pathological
consequences that may  be caused by an uncontrolled immune
response. Large DNA viruses, such as poxviruses and herpesviruses,
have acquired a similar strategy to control the host anti-viral
immunity, and they have incorporated into their genomes genes
encoding soluble versions of host cytokine receptors to be used as
potent inhibitors of cytokine activity (Alcami, 2003). Examples of
virus-encoded homologues of host proteins include the secreted
version of receptors for TNF, IL-1 or IFN-. Due to the struc-
tural nature of the seven-transmembrane-domain the production
of secreted versions of these receptors is not feasible and alter-
native mechanisms have evolved to limit chemokine activity. The
host immune system uses membrane-anchored decoy receptors,
such as the atypical chemokine receptors ACKR1, ACKR2 or ACKR4,
that bind chemokines but do not transduce signals and function as
chemokine scavengers (Graham and McKimmie, 2006; Mantovani
et al., 2006). In contrast, viruses encode secreted proteins of unique
structure not found in host proteins that bind chemokines with high
afﬁnity and block their biological activity (Alcami, 2003; Seet et al.,
2003a).
CKBPs have been found to be produced by non-viral pathogens.
A CKBP secreted by Schistosoma mansoni, a trematode parasite
that infects humans causing schistisomiasis, was  identiﬁed (Smith
et al., 2005). This protein is expressed only in schistosome egg
secretions but not in the other life cycle stages (cercariae, schistoso-
mular, worms) of S. mansoni and interacts with several chemokines,
including CCL2, CCL3, CCL5, CXCL8 and CX3CL1, preventing their
interaction with cellular receptors. Secretion of S. mansoni CKBP
by live eggs modulates the differential recruitment of cells and
the size of the egg granuloma (Smith et al., 2005), suggesting that
smCKBP may  facilitate granuloma formation and the propagation
of the S. mansoni eggs. The evasins encoded by ticks represent a sec-
ond example of non-viral CKBPs (Deruaz et al., 2008; Frauenschuh
et al., 2007). The evasin family comprises three members and are
small proteins of 7–12 kDa produced by the salivary glands. It has
been suggested that evasins may  help to modulate chemokine-
mediated responses and inﬂammation when the ticks feed blood
from their host for several days. Evasin-1 and Evasin-3 show
restricted chemokine binding speciﬁcity, whereas Evasin-4 binds
most CC chemokines. Evasins block the binding of chemokines to
their receptor and inhibit chemokine activity. The crystal structure
of evasins reveals novel protein folds (Deruaz et al., 2008; Dias et al.,
2009). A recent report describes the ﬁrst human secreted protein
that inhibits chemokine activity (Dyer et al., 2014) and is unrelated
to GPCRs. TNF-stimulated gene/protein-6 is secreted and inhibits
neutrophil transendothelial migration, and was known to interact
with several proteins (inter-alpha-inhibitor and thrombospondin-
1) and GAGs. TNF-stimulated gene/protein-6 was found to interact
with CXCL8, to antagonize the CXCL8-heparin interaction and to
impair the transport of CXCL8 across the endothelial cell mono-
layer, which could account for its anti-inﬂammatory effect.
The main function of CKBPs is to inhibit chemokine activity and
the subsequent activation and migration of leukocytes. Most of
the CKBPs inhibit chemokine interaction with their cognate recep-
tors by blocking the receptor binding site in the chemokine. The
ﬁnding that some CKBPs interact with the GAG binding site in the
chemokine and presumably prevent the interaction of chemokines
with GAGs and the formation of a chemokine gradient in tissues
supports the notion that targetting the chemokine–GAG interac-
tion is an efﬁcient strategy to modulate chemokine activity in vivo
(Proudfoot, 2006). The diverse binding speciﬁcity of CKBPs, from
those highly selective for a few chemokines (e.g. evasins, SECRET
domain) to those with broad binding speciﬁcity (e.g. poxvirus 35-
kDa protein, herpesvirus M3)  suggests that CKBPs target a speciﬁc
set of chemokines involved in defence mechanisms that are rel-
evant against particular pathogens. Thus a speciﬁc CKBP may  be
optimized to modulate speciﬁc arms of the immune response and
be efﬁcient to control subsets of leukocytes in particular tissues. The
ﬁnding that gG from HSV-1 and HSV-2 enhance chemokine activ-
ity, rather than inhibit chemokine activity, like the gG orthologues
from animal herpesviruses, illustrate that CKBPs have adapted to
the requirements of speciﬁc viruses. In this case, HSV-1 and HSV-
2 may  beneﬁt from the potentiation of chemokine activity that
recruits immune cells to sites of infection.
Although a considerable amount of work has been done to char-
acterize the biological properties of virus-encoded CKBPs, future
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research should characterize further the ability of CKBPs to modu-
late immune responses in models of infection and inﬂammation.
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